hotspot -WSS

hotspot

author：knowledge 2025-09-27 16:47:50 - browse：8943

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Letters to First Opinion on caregivers, digital health, and more

WSS

Abortion policy in the spotlight at Republican debate

FDA advisory panel to debate high blood pressure devices

Intellia reports positive results for its CRISPR

Meadows told special counsel he could not recall Trump ever declassifying Mar

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Cord blood banking comes at a high cost to babies

hotspot

hotspot

focus

Wildfire smoke exposes gaps in outdoor worker protections

Intellia reports positive results for its CRISPR

ChatGPT in medicine: STAT answers readers' burning questions

Health officials lay out plans to cope with respiratory virus season

Anesthesiologist group: stop taking Ozempic before surgery

With trial win, GSK could get blood cancer drug back on market

After affirmative action ruling, medical educators look to 'holistic review'

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Novavax promises a turnaround & Lilly roils the obesity market

Abortion policy in the spotlight at Republican debate

hotspot

Meadows told special counsel he could not recall Trump ever declassifying Mar

Let's speed up science by embracing open access publishing

FDA's Pazdur wants cancer trials to range beyond China alone

BMI, flaws aside, is found to be useful estimate of body fat in youth

ASCO: Palliative care found as helpful given virtually as in person

Change Healthcare can notify patients about the breach, HHS says

entertainment

focus

hotspot

knowledge